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Abstract _ We have recently demonstrated the beneficial effects of dry olive leaf extract (DOLE) in two preclinical models 
of type 1 diabetes. Here we analyze the potential mechanisms underlying diabetes amelioration at the level of lymph node 
drainage. Treatment of C57BL/6 mice with DOLE during induction of diabetes with multiple low doses of streptozotocin 
(MLD-SZ) modulated cytokine expression and production in pancreatic lymph node cells, thereby changing the balance 
between potentially pathogenic and down-regulating cytokines. These results support the immunoregulatory potential of 
DOLE which takes place at the level of lymph node drainage and preserves the target tissue from autoimmune attack.
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INTRODUCTION
Type 1 diabetes (T1D) is a T-cell mediated disorder 
that results from the autoimmune destruction of 
pancreatic β cells. The progression of T1D in mice 
and possibly in humans alike, is marked by two gen-
eral “checkpoints”: the first is associated with islet 
inflammation (insulitis), but mice remain diabetes-
free because of limited β cell destruction; the second 
corresponds with a shift from “benign” to “aggres-
sive” insulitis when β cells are efficiently destroyed to 
promote overt diabetes (Pop et al., 2005; Stojanovic 
et al., 2008). The destruction of insulin-producing 
cells further results in the loss of metabolic regula-
tion and resultant hyperglycemia and severe se-
quelae of the disease (Azam and Eisenbarth, 2004). 
There is abundant evidence in animal models and to 
a lesser extent in humans with T1D that islet β cell 
destruction results from a disorder in immunoregu-
lation (Rabinovitch and Suarez-Pinzon, 2007). Pan-
creatic lymph nodes (PLN) are reported to be key 
sites for the activation and tolerance induction of 
β-cell-specific T cells (Hoglund et al., 1999; Tritt et 
al., 2008). The lymph node (LN) environment is cru-
cial for the priming of T cells in response to autoanti-
gen and activation of diabetogenic T cells (Hoglund 
et al., 1999). Importantly, regulatory T (Treg) cells 
present in the regional LN continuously control 
organ-specific autoimmune diseases and inflamma-
tory processes (Tritt et al., 2008), underscoring the 
importance of the LN environment in regulating 
immune responses. Both macrophages and T cells 
are thought to exert their diabetogenic potential by 
releasing proinflammatory cytokines of both innate 
and adaptive immunity (Kolb, 1987). Thus, Th1- and 
Th17-type cytokines as well as monokines, correlate 
with development, whereas Th2 and Th3, as well as 
Treg-type cytokines correlate with protection from 
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the disease (Miljkovic et al., 2005; Rabinovitch and 
Suarez-Pinzon, 2007; Stojanovic et al., 2008).
Diabetes mellitus is still not completely curable 
with the present antidiabetic drugs. Although results 
obtained with islet transplantation are promising, 
interfering with the autoimmune response still re-
mains a conceivable strategy for the prevention and 
treatment of T1D. Therefore, herbal drugs are gain-
ing popularity in the treatment of the disease. The 
major merits of herbal medicine seem to be their 
efficacy, low toxicity, low incidence of adverse ef-
fects and low cost, which have rendered them useful 
ingredients in complementary alternative medical 
and/or nutritional supplements. With regard to this, 
the medical potential of the constituents and prod-
ucts of the olive tree, Olea europaea, has been used 
traditionally for various medicinal purposes, includ-
ing several metabolic disorders (Ramirez-Tortosa et 
al., 1999; Esposito et al., 2007). Olive leaves present 
a unique opportunity to study the effects of O. eu-
ropaea-derived polyphenols since the leaf contains 
polyphenols and only a small amount of oleic acid. 
Methanolic extracts of olive leaves contain secoiri-
doids (oleuropein, ligostroside, dimethyloleuropein, 
oleoside), flavonoids (apigenin, kaempferol, luteolin), 
as well as phenolic compounds (caffeic acid, tyrosol, 
hydroxytyrosol) (El and Karakaya, 2009). Recently, 
by utilizing two established preclinical models of au-
toimmune diabetes, cyclophosphamide-accelerated 
diabetes in non-obese diabetic mice and multiple 
low-dose streptozotocin (MLD-SZ)-induced dia-
betes in susceptible mouse strains, we showed that 
the O. europaea-derived components present in a 
polyphenol-enriched dry olive leaf extract (DOLE) 
with oleuropein as major component, can amelio-
rate disease progression (Cvjeticanin et al., 2010). In 
both T1D models, in vivo administration of DOLE 
significantly reduced the clinical signs of diabetes 
and restored insulin expression and release. In the 
peripheral immune system, DOLE acted as a modu-
lator of a variety of inflammatory and immunologi-
cal events, such as nitric oxide production, T lym-
phocyte proliferation, as well as cytokine production 
within the spleen. Given the role of the LN environ-
ment in regulating autoimmune disease, and based 
on the findings from our previous work (Cvjeticanin 
et al., 2010), the present study is focused on the effect 
of DOLE treatment on the production of signature 
cytokines in the PLN as the most relevant organ in 
diabetes pathology.
MATERIALS AND METHODS
Reagents
The extract DOLE EFLA® 943, standardized to 18-
26% of oleuropein, was from Frutarom Switzerland 
td (Wädenswil, Switzerland). As evaluated by phyto-
chemical analysis (Dekanski et al., 2009), the extract 
contained 19.8% oleuropein, 0.52% tannins, 0.02% 
caffeic acid, and 0.29% total flavonoids, including 
0.04% luteolin-7-O-glucoside, 0.07% apigenine-7-
O-glucoside, and 0.04% quercetin. All other reagents 
were purchased from Sigma (St Louis, MO, USA) 
unless otherwise indicated.  
Type 1 diabetes induction and application of DOLE
Genetically susceptible inbred male C57BL/6 mice 
were maintained in our own animal facility (Institute 
for Biological Research “Sinisa Stankovic”, University 
of Belgrade, Serbia) with free access to food and po-
table water. The animals and feed were checked reg-
ularly by appropriate microbiological examination. 
They showed that the animals were not infected with 
common mouse pathogens and that the feed was free 
of microbiological contamination. Immunoinflam-
matory T1D was induced in 8-12 week-old animals 
with multiple low doses of streptozotocin (MLD-SZ, 
40 mg/kg body weight, intraperitoneally for 5 con-
secutive days), exactly as reported previously (Cvjet-
icanin et al., 2009). The treatment with DOLE (40 
mg/kg b.wt per day, for 10 consecutive days) started 
24 h after the last MLD-SZ injection. Clinical dia-
betes was defined by hyperglycemia (blood glucose 
levels >10 mmol/l). The groups of mice (4-5 mice per 
group) used for ex vivo analyses of cytokine produc-
tion were killed on day 15 of diabetes post induction, 
when the treatment with DOLE was completed. All 
experimental procedures were approved by the In-
stitutional Animal Care and Use Committee at the 
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Institute for Biological Research “Sinisa Stankovic” 
and run in accordance to the requirements of the 
European Union regarding handling of experimental 
animals. 
Cell isolation and culture
Pancreatic lymph nodes (PLN) were isolated from 
the DOLE-treated or control diabetic mice organs 
were mechanically disrupted, passed through 40 µm 
nylon mesh filter and collected by centrifugation. 
To determine ex vivo cytokine production, a single 
cell suspension of PLN (5 x 106 cells) was cultured 
in 24-well culture plates in 1 ml of culture medium 
(RPMI-1640 medium supplemented with 5% FCS, 
2 mM l-glutamine, 0.01% sodium pyruvate, 5x10-5 
M 2-mercaptoethanol and antibiotics). After 48 h of 
incubation at 37oC in a humidified atmosphere with 
5% CO2, the media were harvested for cytokine as-
say. 
Determination of cytokine secretion
Cytokines in cell culture supernatants were deter-
mined by sandwich ELISA using MaxiSorp plates 
(Nunck, Rochild, Denmark) and anti-mouse paired 
antibodies according to the manufacturer’s instruc-
tions. Samples were analyzed for murine IL-17, IL-
1β, TNF-α (BD Pharmingen, San Diego, CA, USA), 
IL-6, IL-2, IL-10 (eBioscience, San Diego, CA), IFN-γ 
TGF-β, and IL-4 (R&D, Minneapolis, MN, USA). 
The results were calculated using standard curves 
made on the basis of known concentrations of the 
appropriate recombinant cytokines.
Quantification of cytokines by real time PCR
Total RNA from the PLN cells (5×106) was extracted 
using a mi-Total RNA Isolation Kit (Metabion, Mar-
tinsried, Germany) according to the manufacturer’s 
instructions. The RNA was reverse transcribed using 
Moloney leukemia virus reverse transcriptase and 
random hexamers (both from Fermentas, Vilnius, 
Lithuania). PCR amplification of cDNA (0.4 µl per 
20 µl of PCR reaction) was carried out in an ABI 
PRISM 7000 Sequence Detection System (Applied 
Biosystems, Warrington, UK) using SyBRGreen 
PCR master mix (Applied Biosystems) as follows: 10 
min at 50°C for deoxyuridine triphosphate activa-
tion; 10 min at 95°C for initial denaturation of the 
cDNA followed by 40 cycles (15 s of denaturation 
at 95°C and 60 s for primer annealing and chain ex-
tension step at 60o C). The sequences of the primer 
pairs used for each PCR are listed in Table 1. Data 
Table 1. Nucleotide sequences of primers used in the RT-PCR
Primer sequence (5’ – 3’)       
Cytokine Forward Reverse GenBank acc. no.
IL-1β GCTGAAAGCTCTCCACCTCAATG TGTCGTTGCTTGGTTCTCCTT NM_008361.3
TNF-α CCACGTCGTAGCAAACCAC TGGGTGAGGAGCACGTAGT  NM_013693.2
IL-6 TTCACAAGTCCGGACAGGAG TGGTCTTGGTCCTTAGCCAC  NM_031168.1
IL-2 CCTGAGCAGGATGGAGAATTACA TCCAGAACATGCCGCAGAG  NM_008366.2
IFN-γ CATCAGCAACAACATAAGCGTCA CTCCTTTTCCGCTTCCTGA NM 008337.2
IL-17 GGGAGAGCTTCATCTGT GACCCTGAAAGTGAAGGG NM 010552.3
IL-4 ATCCTGCTCTTCTTTCTCG GATGCTCTTTAGGCTTTCC NM 021283.1
IL-10 TGTGAAAATAAGAG-
CAAGGCAGTG
CATTCATGGCCTTGTAGACAC NM 010548.1
TGF-β CCCTGCCCCTACATTTGGA  ACGGTGATGCGGAAGCAC  NM_011577.1                     
β-actina GGACCTGACAGACTACC GGCATAGAGGTCTTTACGG NM 007393.2
aHousekeeping reporter gene.
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were quantitatively analyzed using SDS 2.1 soft-
ware (Applied Biosystems). Gene expression was 
calculated according to the formula 2-(Cti-Cta), where 
Cti is the cycle threshold of the gene of interest and 
Cta is the cycle threshold value of the housekeeping 
gene, β-actin. The obtained values from the MLD-SZ 
group were arbitrarily attributed a value of one (an 
arbitrary unit). The efficiency of real time PCR was 
in the optimal range of 90-110% (slope of standard 
curves 3.1-3.6) for all of the primer pairs used.
Statistical analysis
The results are presented as means and standard de-
viations. Statistical analysis of differences was made 
using one-way ANOVA, followed by the Student-
Newman-Keuls test for multiple comparisons, or 
Student’s t-test, as appropriate. The statistical pack-
age used was Statistica 6.0 (StatSoft Inc Tulsa, OK, 
USA). The results were considered statistically sig-
nificant with P values of <0.05.
RESULTS
To investigate the immunomodulatory mechanisms 
that may contribute to the beneficial effect of DOLE 
on the autoimmune diabetogenic processes (Cvjeti-
canin et al., 2010), we used the established model 
of DOLE-induced disease modulation in MLD-SZ-
induced diabetic C57BL/6 mice. As judged by blood 
glucose levels, the animals treated with DOLE did 
not develop the clinical signs of diabetes character-
ized by a delayed appearance of sustained hypergly-
cemia (Fig. 1), thus confirming the previously dem-
onstrated beneficial effects of the extract.
Because pro-inflammatory cytokines contribute 
to the pathogenesis of T1D development, whereas 
anti-inflammatory cytokines are associated with pro-
tection from the disease, we determined the effects 
of DOLE treatment on diabetes-associated cytokine 
production by draining the pancreatic lymph nodes 
(PLN) obtained from animals in which the disease 
with MLD-SZ was induced 15 days before. The levels 
of both pro-inflammatory (IL-1β, TNF-α, IL-6, IL-
2, IFN-γ, IL-17) and anti-inflammatory cytokines 
(IL-4, IL-10, TGF-β) in the supernatants of the cells 
cultured without any additional in vitro stimulation, 
were measured by ELISA. As can be seen in Fig. 2, 
DOLE treatment significantly reduced the levels of 
Fig. 1. Effect of DOLE treatment on the development of hyperglycemia induced by MLD-SZ. Blood glucose levels in MLD-SZ-treated 
control mice (n=5) and MLD-SZ + DOLE-treated mice (n=5). *P < 0.05 refers to control MLD-SZ-treated mice.  
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Fig. 2. Effect of DOLE treatment on PLN cytokine production. PLN were isolated from day-15 MLD-SZ-treated control mice and MLD-
SZ + DOLE-treated mice. Cytokine protein levels in PLN culture supernatants were determined by ELISA. Each column represents the 
mean value of five mice per group ± SD. *P < 0.05 refers to control MLD-SZ-treated mice.
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Fig. 3. Effect of DOLE treatment on PLN cytokine expression. The expression of genes in PLN obtained from day-15 MLD-SZ-treated 
control mice and MLD-SZ + DOLE-treated mice was determined by real-time PCR. Expression levels are shown as arbitrary units nor-
malized to expression of the housekeeping gene β-actin. *P < 0.05 refers to control MLD-SZ-treated mice.
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two pro-inflammatory cytokines, IFN-γ and IL-17, 
compared with the control diabetic mice. On the 
contrary, in the DOLE-treated mice a substantial 
increase of IL-4, and slight, but significantly higher 
TGF-β production were observed. However, there 
was no significant difference between the groups in 
the levels of the other cytokines examined, although 
the tendency of an IL-2 rise was observed in the 
DOLE-treated mice (Fig. 2). 
To correlate these findings with the presence of 
cytokine gene expression in vivo, we analyzed and 
compared the levels of cytokine mRNA in the PLN 
of DOLE-treated versus untreated MLDS-induced 
animals. As revealed by real-time PCR (Fig. 3), IL-2 
expression in the PLN of DOLE-treated mice was 
upregulated when compared with that in the con-
trol diabetic mice, whereas the message for IFN-γ 
was significantly downregulated. Regarding other 
cytokines examined there were no significant differ-
ences between the two groups (Fig. 3).
DISCUSSION
Effective T1D therapy requires the elimination and/
or regulation of T cell clones that initiate and perpet-
uate the damage of the pancreatic β cells. The present 
study confirms our previous findings that the regu-
latory effects of DOLE on the immune system can 
be used to prevent diabetes induced with MLD-SZ 
(Cvjeticanin et al., 2010). Moreover, the present re-
sults demonstrate that DOLE profoundly modulates 
the cytokine profile which takes place in the PLN, 
the compartment relevant to the target tissue, which 
is crucial for both initiation and perpetuation of the 
disease (Hoglund et al., 1999; Tritt et al., 2008) and 
provide evidence that the observed protective effect 
is associated, at least in part, with a modulation of cy-
tokine production changing the balance between po-
tentially pathogenic and down-regulating cytokines. 
The present study, to the best of our knowledge, 
is the first demonstration that the cytokine profiles in 
the PLN of DOLE-treated T1D-induced mice were 
clearly changed when compared to the T1D animals. 
Although multiple mechanisms might participate in 
the DOLE-induced amelioration of T1D, the initial 
DOLE effects at the level of PLN might have the sub-
stantial influence on the disease development. In sup-
port of this, it was reported that during the course of 
T1D in NOD mice, there had been changes in gene 
expression specific to the PLN microenvironment, 
and those changes may dictate the fate of the im-
mune response even before insulitis is present (Ko-
dama et al., 2008). In addition, the removal of PLN 
prevents diabetes in NOD mice, thus suggesting that 
PLN are required for the priming of β cell reactive T 
cells in NOD mice (Gagnerault et al., 2002). Moreo-
ver, it was recently suggested that genes influencing 
disease-specific Treg will contribute more directly 
to susceptibility and resistance to an organ-specific 
autoimmune disease when acting at the level of pri-
mary LN drainage at a given target organ than when 
acting systemically (Del Rio et al., 2011).
The expression of the proinflammatory cytokines 
IFN-γ and IL-17 is positively correlated to the induc-
tion and progression of T1D (Rabinovitch and Sua-
rez-Pinzon, 2007; Cvjeticanin et al., 2010). In agree-
ment with this, the present results demonstrate that 
DOLE profoundly suppressed the production of both 
these cytokines by local LN cells. Having in mind the 
above-mentioned role for regional LN in the diabe-
togenic process, the inhibition of IFN-γ and IL-17 
by DOLE in this compartment seems to be a valid 
explanation for the beneficial effect of the extract in 
T1D. However, mRNA expression was significantly 
reduced only for IFN-γ, while IL-17 expression was 
only slightly impaired, without reaching statistical 
significance. This could be a consequence of the dif-
ferent kinetics of cytokine expression versus protein 
secretion. In addition to these Th-derived proin-
flammatory cytokines, the other cytokines which 
are mainly derived from macrophages (such as IL-1, 
TNF-α, and IL-6) may have prominent proinflamma-
tory functions acting downstream of Th1/Th17 cell-
mediated autoimmunity (Lukic et al., 1998; Stosic-
Grujicic et al., 2008). Although we show herein the 
suppression of MLD-SZ-induced diabetes by DOLE 
in the face of ongoing inflammation, the obtained 
results suggest that DOLE did not significantly af-
fect innate inflammatory cytokine production. The 
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observed lack of DOLE activity could be explained 
by a paucity of macrophages within LN tissue. 
IL-2, another Th1-type cytokine long known to 
induce T cell growth and activate T cell immune re-
sponses, has more recently been recognized to be cru-
cial for the induction of immune tolerance (Mallek 
and Bayer, 2004). Thus, IL-2 is essential in downregu-
lating the expansion of antigen-specific autoreactive 
T cells by inducing apoptotic cell death and by stim-
ulating the proliferation and function of Treg cells, 
thereby maintaining self tolerance (Rabinovitch and 
Suarez-Pinzon, 2007). In addition, immunotherapies 
that increase IL-2 production and/or action may cor-
rect a deficiency in IL-2 production that appears to 
underlie the autoimmunity of T1D, thereby restoring 
immune self-tolerance to islet β cells and preventing 
T1D (Rabinovitch and Suarez-Pinzon, 2007). Impor-
tantly, we showed that under the influence of DOLE, 
the expression of IL-2 was significantly up-regulated 
in the LN of MLD-SZ-treated mice, although the 
amount of released protein was not significantly in-
fluenced. Hypothetically, the lack of IL-2 protein ac-
cumulation versus high mRNA expression may have 
been due to the consumption of IL-2 by Treg cells. 
Interestingly, in a model of inflammatory bowel dis-
ease, it has been shown that deprivation of IL-2 by 
CD4+CD25+ regulatory T cells may induce apoptosis 
of effector T cells (Pandyan et al., 2007). 
It is well established that Th2/3-type cytokines 
correlate with protection from T1D (Rabinovitch 
and Suarez-Pinzon, 2007; Stosic-Grujicic et al., 
2008). Evidence is provided that the progression of 
“benign” to “aggressive” insulitis corresponds with a 
temporal decrease of TGF-β and FoxP3 co-expressing 
CD4+CD25+ Treg cells in the pancreatic lymph nodes 
(PLN) (Pop et al., 2005). Furthermore, TGF-β may 
have a direct effect on the induction of Treg function 
in an autocrine manner (Piccirilo et al., 2002), as well 
as in enhancing Th2 cell expansion and repressing 
the induction of Th17 (Zhu et al., 2009). From this, 
limiting the amounts of TGF-β that are produced 
during diabetes induction would be expected to 
reduce the efficiency of such a mechanism. Results 
presented herein clearly show that in vivo treatment 
with DOLE up-regulated the production of IL-4, 
the key driver of Th2 responses, as well as of TGF-β. 
Our present findings thus revealed the dominance of 
Th2/3-type over Th1/Th17 signature cytokines if the 
cells were obtained from DOLE-treated mice, thus 
shifting the balance towards a beneficial cytokine 
milieu.
Collectively, it seems that DOLE protects mice 
from MLD-SZ-induced T1D by suppression of a 
cascade of events associated with the progression of 
the disease from “mini autoimmune response” into 
chronic immune-mediated damage of endocrine 
pancreas. The potent bioactivity and low toxicity 
of DOLE components have rendered them useful 
ingredients in complementary alternative medical 
and nutritional supplements. These data warrant 
additional studies for the prospective translation of 
DOLE to the treatment of T1D in humans.
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